Ultragenyx Pharmaceutical Inc. (RARE): Cost of Revenue
Older than the company's other figures. The latest Cost of Revenue is for the year ended 2018-12-31, while the company's latest annual report covers the year ended 2025-12-31. Its later filings do not report this line under the concept TickerFacts maps.
$1.15M
Year ended 2018-12-31
| Period ended | Cost of Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2018-12-31 | $1.15M | n/m | 2019-02-20, From 2018-01-01 |
| 2017-12-31 | $1.0K | n/a | 2019-02-20, From 2017-01-01 |